Marta Rial-Crestelo, Marek Lubusky, Mauro Parra-Cordero, Ladislav Krofta, Anna Kajdy, Eyal Zohav, Elena Ferriols-Perez, Rogelio Cruz-Martinez, Marian Kacerovsky, Elena Scazzocchio, Lucie Roubalova, Pamela Socias, Lubomir Hašlík, Jan Modzelewski, Eran Ashwal, Julia Castellá-Cesari, Monica Cruz-Lemini, Eduard Gratacos, Francesc Figueras
BACKGROUND: The cerebroplacental ratio is associated with perinatal mortality and morbidity, but it is unknown whether routine measurement improves pregnancy outcomes. We aimed to evaluate whether the addition of cerebroplacental ratio measurement to the standard ultrasound growth assessment near term reduces perinatal mortality and severe neonatal morbidity, compared with growth assessment alone. METHODS: RATIO37 was a randomised, open-label, multicentre, pragmatic trial, conducted in low-risk pregnant women, recruited from nine hospitals over six countries...
January 11, 2024: Lancet